IP Library Granted Patent US 12,201,849
Granted Patent B2
US 12,201,849 · App. 17/786,659 · Granted Jan 21, 2025

Planning radiation therapy using a personalized hematologic risk score

Inventors: Pedro Jorge Da Silva Rodrigues (Veldhoven, NL); Maria Luiza Bondar (Waalre, NL); Andreia Maria Araujo Trindade Rodrigues (Veldhoven, NL); Vanda Lucia De Carvalho Vittorino De Almeida (Veldhoven, NL)
Assignee: Elekta Inc.
A61N5/1031G16H20/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,849
App. No.
17/786,659
Granted
Jan 21, 2025
Kind
B2
Abstract

Thereto a method and a system for planning radiation therapy are provided, as well as an arrangement for radiation therapy planning and a computer program product for carrying out the method. For planning the radiation therapy, the following steps are performed. Patient data of a subject to be treated is received as well as image data of the subject to be treated. The image data comprises anatomical image data of one or more organs at risk associated with the functioning of the immune system. Next, the patient 122 data and the image data are processed to obtain a risk score for the one or more organs at risk associated with the functioning of the immune system. The risk score is indicative of the risk of hematologic toxicity in the subject to be treated in response to the radiation therapy. Then the radiation therapy treatment is planned using the obtained risk score.

Claims (30)

1. A method for planning radiation therapy the method comprising:

receiving patient data of a subject to be treated;

receiving image data of the subject to be treated, which image data comprises anatomical image data of one or more organs at risk associated with a functioning of an immune system;

processing the patient data and the image data to obtain a risk score for the one or more organs at risk associated with the functioning of the immune system, which risk score is indicative of a risk of hematologic toxicity in the subject to be treated in response to the radiation therapy; and

planning a radiation therapy treatment using the obtained risk score to reduce the risk of hematologic toxicity in the subject to be treated.

2. The method according to claim 1 , wherein the image data of the subject further includes functional image data for the one or more organ at risk associated with the functioning of the immune system, and wherein the risk score is obtained by applying a functional model of the organs at risk.

3. The method according to claim 1 , wherein the risk score is obtained by applying a model based on historic patient data.

4. The method according to claims 1 , wherein the patient data comprises blood cell counts in the subject, in particular lymphocyte counts in the subject.

5. The method according to any of claims 1-4 , wherein the one or more organs at risk associated with the functioning of the immune system are at least one of: a thymus, an area of active bone marrow, vertebra, a heart, heart chambers, or a large blood vessel.

6. The method according to claim 1 , wherein planning a radiation therapy treatment comprises selecting a type of radiation therapy; and calculating a radiation therapy plan for the selected type of radiation therapy.

7. The method of claim 6 , wherein the type of radiation therapy includes at least one of an intensity modulated radiation therapy, a volumetric modulated radiation therapy, a photon radiation therapy with a non-coplanar beam arrangement, and a proton or other particle therapy.

8. The method according to claims 1 , wherein the image data further comprises anatomical image data of at least a target structure; and the method further comprises receiving one or more clinical goals for the target structure and the one or more organs at risk.

9. The method according to claim 8 , wherein planning the radiation therapy treatment comprises adjusting the clinical goals using the obtained risk score.

10. The method according to claims 8 , wherein planning the radiation therapy treatment comprises calculating organ sparing probability scores for the or more organs at risk associated with the functioning of the immune system for each of a group of possible radiation therapy treatment options.

11. The method according to claim 10 , wherein the radiation therapy treatment options are different geometric beam arrangements in intensity modulated radiation therapy.

12. A system for planning radiation therapy comprising:

an input for receiving patient data of a subject to be treated;

an input for receiving image data of the subject to be treated, which image data comprises anatomical image data of at least one organ at risk associated with a functioning of an immune system;

a risk score calculation unit configured to process the patient data and the image data to obtain a risk score for one or more organs at risk associated with the functioning of the immune system indicative of a risk of hematologic toxicity in the subject to be treated in response to the radiation therapy; and

a radiation therapy planning unit configured to select a radiation therapy plan using the obtained risk score to reduce the risk of hematologic toxicity in the subject to be treated.

13. The system according to claim 12 , further comprising a display unit configured to display the risk score of the at least one organ at risk.

14. The system according to claim 13 , wherein the display is further configured to display organ sparing probability scores for the organs at risk associated with the functioning of the immune system for each of a group of possible radiation therapy options.

15. An arrangement for radiation therapy planning comprising:

one or more imaging devices configured to generate image data of a subject to be treated;

a patient information database configured to store and provide patient data; and

a system for planning radiation therapy comprising:

an input for receiving patient data of a subject to be treated:

an input for receiving image data of the subject to be treated, which image data comprises anatomical image data of at least one organ at risk associated with a functioning of an immune system;

a risk score calculation unit configured to process the patient data and the image data to obtain a risk score for one or more organs at risk associated with a functioning of the immune system indicative of the risk of hematologic toxicity in the subject to be treated in response to the radiation therapy; and

a radiation therapy planning unit configured to select a radiation therapy plan using the obtained risk score to reduce a risk of hematologic toxicity in the subject to be treated.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2024
From: KONINKLIJKE PHILIPS N.V.
To: ELEKTA INC.
Reel/Frame 067966/0289 →
LICENSE Recorded Jun 28, 2024
From: ELEKTA INC.
To: KONINKLIJKE PHILIPS N.V.
Reel/Frame 068334/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2022
From: DA SILVA RODRIGUES, PEDRO JORGE; BONDAR, MARIA LUIZA; TRINDADE RODRIGUES, ANDREIA MARIA ARAUJO; VITTORINO DE ALMEIDA, VANDA LUCIA DE CARVALHO
To: KONINKLIJKE PHILIPS N.V.
Reel/Frame 060235/0259 →
Priority Claims (1)
EP 19219251 · Dec 23, 2019 · regional
Continuity (1)
Related Publication 20230021147A1 · Jan 19, 2023
References Cited (31)
US 20160129282A1 · Yin · 2016 [cited by examiner]
US 20170259083A1 · Nakatsugawa · 2017 [cited by examiner]
EP 3842097 · 2021 [cited by applicant]
WO 2021130047 · 2021 [cited by applicant]
PCT International Search Report, International application No. PCT/EP2020/086060, Feb. 12, 2021. [cited by applicant]
Fleming C. et al., “Normal Tissue Considerations and Dose-Volume Constraints in the Moderately Hypofractionated Treatment of Non-Small Cell Lung Cancer”, Radiotherapy and Oncology, vol. 119, No. 3, pp. 423-431, Jun. 201… [cited by applicant]
Braley J. D. et al., “Sandard-Dose Versus High-Dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin Plus Paclitaxel with or without Cetuximab for Patients with Stage IIIA or IIIB Non-Small-Cell Lung… [cited by applicant]
Pike L. R. G. et al, “The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors”, International Journal of Radiation Oncology, Biology, Ph… [cited by applicant]
Weinreich M. A. et al., “Thymic Emigration: When and How T Cells Leave Home, ”, Journal of Immunology, Baltimore, MD, vol. 181, No. 4, pp. 2265-2270, Aug. 2008. [cited by applicant]
Rezzani R. et al., “Thymus and Aging: Morphological, Radiological, and Functional Overview”, AGE, vol. 36, No. 1, pp. 313-351, Feb. 2014. [cited by applicant]
Lepletier A. et al., “Inflammation and Thymus Ageing”, Frontiers of Hormone Research, vol. 48, pp. 19-36, 2017. [cited by applicant]
Sun D.-P. et al., “Thymic Hyperplasia After Chemotherapy in Adults with Mature B Cell Lymphoma and its Influence on Thymic Output and CD4+ T Cells Repopulation”, Oncoimmunology, vol. 5, No. 5, Feb. 2016. [cited by applicant]
Sfikakis P. P. et al., “Age-Related Thymic Activity in Adults Following Chemotherapy-Induced Lymphopenia”, European Journal of Clinical Investigation, vol. 35, Issue 6, pp. 380-387, 2005. [cited by applicant]
Ito R. et al., “Late Effects of Exposure to Ionizing Radiation and Age on Human Thymus Morphology and Function”, Radiation Research, vol. 187, No. 5, pp. 589-598, 2017. [cited by applicant]
Dong P. et al., “4π Noncoplanar Stereotactic Body Radiation Therapy for Centrally Located or Larger Lung Tumors”, International Journal of Radiation Oncology, Biology and Physics, vol. 86, No. 3, pp. 407-413, Jul. 2013. [cited by applicant]
Wu K. et al., “Statistical Atlas-Based Morphological Variation Analysis of the Asian Humerus: Towards Consistent Allometric Implant Positioning”, International Journal of Computer Assisted Radiology and Surgery, vol. 10… [cited by applicant]
Abravan A. et al., “Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer”, Molecular Imaging and Biology, vol. 21, pp. 391-398,… [cited by applicant]
Tsujikawa T. et al., “18F-FLT PET/MRI for Bone Marrow Failure Syndrome—Initial Experience”, EJNMMI Research, vol. 9, No. 1, Feb. 2019. [cited by applicant]
Leimgruber A. et al., “Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by 18-FFLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer”, Journal o… [cited by applicant]
Hyer D.E. et al., “Estimation of Organ Doses from Kilovoltage Cone-Beam CT Imaging Used During Radiotherapy Patient Position Verification”, Medical Physics, vol. 37, No. 9, pp. 4620-4626, Sep. 2010. [cited by applicant]
Pyone Y.Y. et al., “Determination of Effective Doses in Image-Guided Radiation Therapy System”, Journal of Physics: Conference Series, vol. 694, p. 012007, 2016. [cited by applicant]
Nasseri F. et al., “Clinical and Radiologic Review of the Normal and Abnormal Thymus: Pearls and Pitfalls”, RadioGraphics, vol. 30, No. 2, pp. 413-418, 2010. [cited by applicant]
Viglianti B.L. et al., “Common Pitfalls in Oncologic FDG PET/CT Imaging”, Journal of American Osteopathic College of Radiology, vol. 7, Issue 1, 2018. [cited by applicant]
McGuire S.M. et al., “[18F]FLT PET Quantification of Bone Marrow Response to Radiation Dose”, International Journal of Radiation, Oncology, Biology, Physics, vol. 81, No. 3, pp. 888-893, Nov. 2012. [cited by applicant]
Scarlli M. et al., “FLT PET/CT Imaging of Metastatic Prostate Cancer Patients Treated with pTVG-HP DNA Vaccine and Pembrolizumab”, Journal for Immunotherapy of Cancer, vol. 7, issue 1, pp. 23, Jan. 2019. [cited by applicant]
Kuncman L. et al., “Bone Marrow Sparing RT in Era of Immunotherapy”, Journal of Oncology 2017, vol. 67, No. 5, pp. 301-307, 2017. [cited by applicant]
Aide N. et al., “FDG PET/CT for Assessing Tumour Response to Immunotherapy”, European Journal of Nuclear Medicine ad Lolecular Imaging, vol. 46, p. 238-250, 2019. [cited by applicant]
“European Application Serial No. 19219251.6, Extended European Search Report mailed May 28, 2020”, 6 pgs. [cited by applicant]
“European Application Serial No. 19219251.6, Noting of Loss of Rights mailed Jan. 25, 2022”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT EP2020 086060, Written Opinion mailed Feb. 12, 2021”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT EP2020 086060, International Preliminary Report on Patentability mailed Jul. 7, 2022”, 7 pgs. [cited by applicant]
Cited By (1)
US 12,544,593